mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease? Who Can Advance to HSCT? Can Frontline Dasatinib+Blina Help Achieve MRD? What Is the ORR With Ino?
By
2nd SOHO Italian Conference
FEATURING
Cristina Papayannidis
By
2nd SOHO Italian Conference
FEATURING
Cristina Papayannidis
Login to view comments.
Click here to Login